162
/ Yangshengtang
- LARVOL DELTA
Home
Next
Prev
1 to 7
Of
7
Go to page
1
July 17, 2024
A Clinical Study of 162 in Subjects With Chronic Hepatitis B Virus Infection
(clinicaltrials.gov)
- P1 | N=1 | Terminated | Sponsor: Yangshengtang Co., Ltd | N=10 ➔ 1 | Initiation date: Feb 2024 ➔ Jun 2024 | Not yet recruiting ➔ Terminated; Enrollment difficulty
Enrollment change • Trial initiation date • Trial termination • Hepatitis B • Hepatology • Infectious Disease • Inflammation
December 06, 2023
A Clinical Study of 162 in Subjects With Chronic Hepatitis B Virus Infection
(clinicaltrials.gov)
- P1 | N=10 | Not yet recruiting | Sponsor: Yangshengtang Co., Ltd
New P1 trial • Hepatitis B • Hepatology • Infectious Disease • Inflammation
November 27, 2023
Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects
(clinicaltrials.gov)
- P1 | N=20 | Completed | Sponsor: Yangshengtang Co., Ltd | Recruiting ➔ Completed | N=34 ➔ 20
Enrollment change • Trial completion • Hepatitis B • Hepatology • Infectious Disease • Inflammation
August 01, 2023
Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects
(clinicaltrials.gov)
- P1 | N=34 | Recruiting | Sponsor: Yangshengtang Co., Ltd | Trial completion date: Jul 2023 ➔ Oct 2023
Trial completion date • Hepatitis B • Hepatology • Infectious Disease • Inflammation
January 31, 2023
Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects
(clinicaltrials.gov)
- P1 | N=34 | Recruiting | Sponsor: Yangshengtang Co., Ltd | Trial completion date: Aug 2022 ➔ Jul 2023 | Trial primary completion date: Aug 2022 ➔ Jul 2023
Trial completion date • Trial primary completion date • Hepatitis B • Hepatology • Infectious Disease • Inflammation
June 08, 2022
Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects
(clinicaltrials.gov)
- P1 | N=34 | Recruiting | Sponsor: Yangshengtang Co., Ltd | Not yet recruiting ➔ Recruiting
Enrollment open • Hepatitis B • Hepatology • Infectious Disease • Inflammation
April 05, 2022
Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects
(clinicaltrials.gov)
- P1 | N=34 | Not yet recruiting | Sponsor: Yangshengtang Co., Ltd
New P1 trial • Hepatitis B • Hepatology • Infectious Disease • Inflammation
1 to 7
Of
7
Go to page
1